Acura Pharmaceuticals Inc's ROA from the fourth quarter of 2021 to the fourth quarter of 2020 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Acura Pharmaceuticals Inc's ROA in the fourth quarter of 2021?
Acura Pharmaceuticals Inc recorded a cumulative net loss of $-1 million during 12 months ending in the fourth quarter of 2021, resulting in a negative return on assets (ROA) of -57.83%.

However, within the Healthcare sector 931 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2021 from 4545 to 5403.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2021) IV. Quarter	(Sep 30 2021) III. Quarter	(Jun 30 2021) II. Quarter	(Mar 31 2021) I. Quarter	(Dec 31 2020) IV. Quarter
Y / Y Total Assets Change	-50.46 %	-36.06 %	-25.24 %	-4.29 %	-32.24 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-1	-1	-2	-1	-1
Return On Assets (TTM)	-57.83 %	-66.19 %	-80.89 %	-41.58 %	-57.01 %
ACUR's Total Ranking	# 5403	# 4545	# 4670	# 4172	# 4824
Total Assets (TTM) in million	1	1	2	2	2
Seq. Total Assets Change	-38.83 %	-25.84 %	-1.15 %	10.48 %	-21.06 %
Seq. Net Income Change	-	-	-	-	-

ACUR's 5 Years Annual ROA >> Back to ACUR Management Effectiveness >> Compare ACUR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 465
Sector	# 932
Overall	# 5281

Return On Assets Statistics
High	Average	Low
2.84 %	-80.09 %	-236.39 %
(Jun 30 2020)		(Jun 30 2019)

Financial Statements
Acura Pharmaceuticals Inc's Assets	$ 1 million	ACUR's Balance sheet
Acura Pharmaceuticals Inc's Income	$ 0 million	Quarterly ACUR's Income Statement
ACUR's Income by Division		See ACUR's Income by Division

Annual Return On Assets	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018	(Dec 31 2017) FY 2017
Y / Y Total Assets Change	-50.46 %	-32.24 %	19.05 %	-53.26 %	-43.91 %
Total Assets in million	1	2	3	2	5
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-1	-1	-4	-4	-6
Annual Return On Assets	-102.21 %	-69.59 %	-147.31 %	-178.53 %	-123.41 %

ACUR's 5 Years Annual ROA >> Back to ACUR Management Effectiveness >> Compare ACUR ROA to its Competitors

More Return On Assets Ratios
ACUR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ACUR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ACUR's Competitors
Subscribers only: Roa for Acura Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for ACUR's Customers

You may also want to know
ACUR's Roi	ACUR's Inventory Turnover Ratio	ACUR's Growth Rates	ACUR's Dividend Comparisons
	ACUR's Profitability Ratios	ACUR's Asset Turnover Ratio	ACUR's Dividend Growth
ACUR's Roe	ACUR's Valuation Ratios	ACUR's Financial Strength Ratios	ACUR's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2021, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.